Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,346,624
  • Shares Outstanding, K 1,765,868
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • 60-Month Beta 0.61
  • Price/Sales 5.24
  • Price/Cash Flow 10.16
  • Price/Book 35.28
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 16.78% ( -0.58%)
  • Historical Volatility 25.55%
  • IV Percentile 8%
  • IV Rank 8.61%
  • IV High 29.42% on 04/12/24
  • IV Low 15.58% on 09/01/23
  • Put/Call Vol Ratio 0.61
  • Today's Volume 15,100
  • Volume Avg (30-Day) 24,660
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 369,776
  • Open Int (30-Day) 361,115

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 3.06
  • Number of Estimates 9
  • High Estimate 3.11
  • Low Estimate 3.00
  • Prior Year 2.91
  • Growth Rate Est. (year over year) +5.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
157.65 +3.72%
on 04/26/24
170.37 -4.02%
on 04/23/24
+1.85 (+1.14%)
since 04/15/24
3-Month
157.65 +3.72%
on 04/26/24
182.89 -10.59%
on 03/12/24
-13.07 (-7.40%)
since 02/15/24
52-Week
130.96 +24.86%
on 06/28/23
182.89 -10.59%
on 03/12/24
+16.93 (+11.55%)
since 05/15/23

Most Recent Stories

More News
3 Magnificent Stocks That Are Passive Income Machines

These three companies have track records that should please investors.

LLY : 781.80 (+2.51%)
ABBV : 163.42 (+1.13%)
NVS : 103.11 (-0.19%)
What Is the Dividend Payout for AbbVie Stock?

The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well.

ABBV : 163.42 (+1.13%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 28.78 (+1.41%)
ABBV : 163.42 (+1.13%)
JNJ : 152.33 (+0.63%)
RHHBY : 31.4200 (+1.52%)
GMAB : 30.25 (+2.44%)
AZN : 76.94 (-0.13%)
DSNKY : 35.1350 (+1.31%)
MRK : 131.19 (+1.97%)
LLY : 781.80 (+2.51%)
NVO : 134.42 (+1.13%)
5 Standout Healthcare Dividend Stocks to Consider Now

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

JNJ : 152.33 (+0.63%)
MRK : 131.19 (+1.97%)
ABBV : 163.42 (+1.13%)
PFE : 28.78 (+1.41%)
MDT : 84.52 (+0.26%)
Earn $1000 Every Month From These 3 Stocks

All 3 companies pay growing dividends.

PFE : 28.78 (+1.41%)
MO : 45.82 (+0.70%)
ABBV : 163.42 (+1.13%)
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

These pharmaceutical companies are top-notch dividend growth stocks for the future.

NVO : 134.42 (+1.13%)
LLY : 781.80 (+2.51%)
ABBV : 163.42 (+1.13%)
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees

These are low-risk stocks with high yields.

ABBV : 163.42 (+1.13%)
T : 17.24 (-0.35%)
XOM : 118.25 (+0.49%)
QULIPTAâ„¢ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults

QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across all frequencies,...

ABBV : 163.42 (+1.13%)
Stocks Settle Higher on Solid Earnings and Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +1.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.13%. US stock indexes...

$SPX : 5,299.58 (+1.01%)
SPY : 528.89 (+1.07%)
$DOWI : 39,836.84 (+0.70%)
DIA : 398.52 (+0.74%)
$IUXX : 18,579.91 (+1.40%)
QQQ : 452.62 (+1.50%)
ZNM24 : 109-225 (+0.56%)
SMCI : 941.35 (+14.47%)
NVDA : 946.37 (+3.59%)
AMD : 158.96 (+3.79%)
KLAC : 756.68 (+3.67%)
AVGO : 1,431.90 (+3.76%)
Stocks Climb on Strength in Chips Stocks and Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. US stock indexes this morning...

$SPX : 5,299.58 (+1.01%)
SPY : 528.89 (+1.07%)
$DOWI : 39,836.84 (+0.70%)
DIA : 398.52 (+0.74%)
$IUXX : 18,579.91 (+1.40%)
QQQ : 452.62 (+1.50%)
ZNM24 : 109-225 (+0.56%)
MU : 127.07 (+1.81%)
NVDA : 946.37 (+3.59%)
AMD : 158.96 (+3.79%)
GFS : 54.27 (-0.22%)
KLAC : 756.68 (+3.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 165.19
2nd Resistance Point 163.72
1st Resistance Point 162.65
Last Price 163.42
1st Support Level 160.12
2nd Support Level 158.65
3rd Support Level 157.58

See More

52-Week High 182.89
Last Price 163.42
Fibonacci 61.8% 163.05
Fibonacci 50% 156.93
Fibonacci 38.2% 150.80
52-Week Low 130.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar